Hospital operator HCA Healthcare (NYSE: HCA) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 8.7% year on year to $20.23 billion. The company expects the full year’s revenue to be around $78.25 billion, close to analysts’ estimates. Its GAAP profit of $7.62 per share was 2.2% above analysts’ consensus estimates.
Is now the time to buy HCA Healthcare? Find out by accessing our full research report, it’s free.
HCA Healthcare (HCA) Q2 CY2026 Highlights:
- Revenue: $20.23 billion vs analyst estimates of $19.76 billion (8.7% year-on-year growth, 2.4% beat)
- EPS (GAAP): $7.62 vs analyst estimates of $7.46 (2.2% beat)
- Adjusted EBITDA: $4.03 billion vs analyst estimates of $4.00 billion (19.9% margin, 0.6% beat)
- EPS (GAAP) guidance for the full year is $29.60 at the midpoint, missing analyst estimates by 1.2%
- EBITDA guidance for the full year is $15.75 billion at the midpoint, in line with analyst expectations
- Free Cash Flow Margin: 5.5%, down from 16.3% in the same quarter last year
- Market Capitalization: $83.52 billion
Company Overview
With roots dating back to 1968 and a network spanning 20 states, HCA Healthcare (NYSE: HCA) operates a network of 190 hospitals and 150+ outpatient facilities providing a full range of medical services across the US and England.
Revenue Growth
Examining a company’s long-term performance can provide clues about its quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul. Unfortunately, HCA Healthcare’s 6.8% annualized revenue growth over the last five years was mediocre. This wasn’t a great result compared to the rest of the healthcare sector, but there are still things to like about HCA Healthcare.
We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. HCA Healthcare’s annualized revenue growth of 6.8% over the last two years aligns with its five-year trend, suggesting its demand was consistently weak. 
This quarter, HCA Healthcare reported year-on-year revenue growth of 8.7%, and its $20.23 billion of revenue exceeded Wall Street’s estimates by 2.4%.
Looking ahead, sell-side analysts expect revenue to grow 2.6% over the next 12 months, a deceleration versus the last two years. This projection doesn’t excite us and implies its products and services will face some demand challenges. At least the company is tracking well in other measures of financial health.
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.
Operating Margin
Operating margin is an important measure of profitability as it shows the portion of revenue left after accounting for all core expenses — everything from the cost of goods sold to advertising and wages. It’s also useful for comparing profitability across companies with different levels of debt and tax rates because it excludes interest and taxes.
HCA Healthcare has managed its cost base well over the last five years. It demonstrated solid profitability for a healthcare business, producing an average operating margin of 17.1%.
Looking at the trend in its profitability, HCA Healthcare’s operating margin decreased by 7.1 percentage points over the last five years. This raises questions about the company’s expense base because its revenue growth should have given it leverage on its fixed costs, resulting in better economies of scale and profitability.
in line with the same quarter last year. This indicates the company’s overall cost structure has been relatively stable.
Earnings Per Share
We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable.
HCA Healthcare’s EPS grew at 15.4% compounded annual growth rate over the last five years, higher than its 6.8% annualized revenue growth. However, this alone doesn’t tell us much about its business quality because its operating margin didn’t improve.
We can take a deeper look into HCA Healthcare’s earnings quality to better understand the drivers of its performance. A five-year view shows that HCA Healthcare has repurchased its stock, shrinking its share count by 33%. This tells us its EPS outperformed its revenue not because of increased operational efficiency but financial engineering, as buybacks boost per share earnings. 
In Q2, HCA Healthcare reported EPS of $7.62, up from $6.83 in the same quarter last year. This print beat analysts’ estimates by 2.2%. Over the next 12 months, Wall Street expects HCA Healthcare’s full-year EPS to grow 5.1% from $29.86 to $31.40.
Key Takeaways from HCA Healthcare’s Q2 Results
It was encouraging to see HCA Healthcare beat analysts’ revenue expectations this quarter. On the other hand, its full-year EPS guidance slightly missed and its full-year revenue guidance was in line with Wall Street’s estimates. Overall, this quarter had some positives. The stock traded up 1.2% to $381.05 immediately after reporting.
So should you invest in HCA Healthcare right now? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here (it’s free).
